Almost two years after its launch, eye-focused gene therapy start-up Vedere Bio II is closing its doors, company leaders announced through a LinkedIn post over the weekend.
https://www.pharmalive.com/wp-content/uploads/2023/04/VedereBio-CyrusMozayeni.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-03 10:36:092023-04-03 11:23:09Vedere Bio II closes doors after preclinical studies fall short